Oct. 18-21 was supposed to be a four-day public meeting event, held by the EPA, to discuss if glyphosate is safe. The EPA Scientific Advisory Panel decided to postpone the meetings after heavy lobbying by the agrichemical industry.
Another sign of industry influence over @EPA as @MonsantoCo #glyphosate cancer review delayed https://t.co/p6aSGZinCK via @HuffPostGreen
— carey gillam (@careygillam) October 19, 2016
Biotech companies, including Monsanto, have all influenced the EPA in postponing these important and necessary meetings, saying the speakers will be too biased.
“EPA should replace Dr. Infante with an epidemiologist without such patent bias,” CropLife, which represents the interests of Monsanto and other agribusinesses, told the EPA.
If you liked this article, please donate $5 to keep NationofChange online through November.